Blueprint's avapritinib OK'd in Europe for type of GI tract cancer


As expected, the European Commission approves Blueprint Medicines’ (BPMC -0.7%) Ayvakyt (avapritinib) as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.

Two months ago, the advisory group CHMP adopted a positive opinion backing approval.

Quant rating is Bullish.





READ SOURCE

READ  Boeing boss survives investors' bid to force him to give up one of his three roles

LEAVE A REPLY

Please enter your comment!
Please enter your name here